Cosmo Pharmaceuticals S.p.A. operates as a specialty pharmaceutical company primarily in Italy. The company develops, licenses, and commercializes proprietary pharmaceutical products, primarily for the treatment of inflammatory bowel diseases, colon infections, and other colon diseases, as well as topically treated skin disorders; and manufactures pharmaceutical products for third parties and provides related services. Its products comprise Lialda, Mezavant, and Mesavancol proprietary formulations for mild to moderate ulcerative colitis; Zacol NMX for intestinal disorders; Uceris and Cortiment products for ulcerative colitis; and Low Molecular Weight Heparin MMX for the treatment of Ulcerative Colitis. The company also develops various products, including Rifamycin SV MMX, which is under Phase III clinical trials and is intended for use as an antibiotic; CB-03-01, a steroidal ester, androgen antagonist that is under Phase II clinical trials; CB-17-01, a coloring agent that is used to stain the mucosa to discover pre-cancerous lesions and polyps in the colon and has completed Phase II clinical trials; and CB-01-16, which is under Phase I clinical trials and is intended for the treatment of opioid induced constipation. It has a strategic collaboration agreement with Santarus Inc. The company is headquartered in Lainate, Italy.
cosmo pharmaceuticals spa
(COPN:SIX Swiss Ex)
Via Cristoforo Colombo, 1
Lainate, MI 20020
Phone: 39 0293 33 76 14
Fax: 39 0293 33 76 63www.cosmopharmaceuticals.com
|Alkermes PLC||$44.04 USD||+0.05|
|Depomed Inc||$14.94 USD||+1.78|
|Durect Corp||$1.55 USD||0.00|
|Supernus Pharmaceuticals Inc||$8.96 USD||-0.05|
|Veloxis Pharmaceuticals A/S||kr1.87 DKK||+0.01|
|View Industry Companies|
Sponsored Financial Commentaries
To contact COSMO PHARMACEUTICALS SPA, please visit www.cosmopharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.